I would say that these drugs are a challenge. In the pharmaceutical benefits scheme, we haven't said no to a pharmaceutical for rare diseases except once in the last five to seven years. Many of these drugs are in-patient pharmaceuticals. That means that the TLV is not really responsible for the decisions. Of course, we give a lot of support, and we do have health technology assessments to support the county councils. We're all kind of together in the challenge when it comes to these specialty drugs.
We have a higher willingness to pay when it comes to effective drugs for rare diseases that are really severe and where there are no good alternatives. We have actually developed this further. Last year, the TLV said that we were willing to pay even more. We have managed to subsidize and reimburse the costs of the majority of these drugs. Still, there are a few that are really a problem for us, and we try to develop our own system for handling these. We see that more collaboration with other countries within the Nordic and European area is something that we need to move forward on.